Preparing healthcare companies for success
in the value-based economy

New Access Meter Report
NOW AVAILABLE

more info >

Solutions

Real Endpoints brings a wide range of strategic and operational market access solutions to our clients.

more >

Insights

Real Endpoints is a thought leader within the pharmaceutical industry. We actively publish and lead panels and are frequently quoted in the press.

more >

News and Events

5th Annual Immuno-Oncology BD&L and Investment Forum

Speaker: Roger Longman

Real Endpoints

Taking place on the first day of ASCO, the 5th Annual Immuno-Oncology BD&L and Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering, funding and investment. We expect around 250 delegates and about 30 presentations by listed and private biotechnology companies seeking licensing & investment. Numerous networking opportunities available via an online one-to-one meeting system with dedicated meeting facilities to make the event more transactional.

May 31, 2019

Waldorf Astoria Chicago Hotel

Jeff Berkowitz Takes Helm of Real Endpoints

by PharmaVoice

Real Endpoints, which provides development and implementation of proprietary tools, has named Jeff Berkowitz as CEO and member of the board of directors. Most recently, Mr. Berkowitz served as an executive VP at UnitedHealth Group, CEO of it Optum International business, and as a strategic leader of OptumRx, its PBM, Mr. Berkowitz is a PharmaVOICE Red Jacket - 2014.

October 16, 2018

PharmaVoice

Read full article >

AMCP Nexus

Attendee: Real Endpoints team

The Academy of Managed Care Pharmacy (AMCP) is the nation’s leading professional association dedicated to increasing patient access to affordable medicines, improving health outcomes and ensuring the wise use of health care dollars. Through evidence- and value-based strategies and practices, the Academy’s 8,000 pharmacists, physicians, nurses and other practitioners manage medication therapies for the 270 million Americans served by health plans, pharmacy benefit management firms, emerging care models and government.

October 22, 2018 -
October 25, 2018

Orlando, FL

event >

Must Sky-High Prices ‘Come on Down’ Before the Price Is Right?

by Richard Mark Kirkner

The first gene therapy to treat an inherited disease is out of the gate, but with a very high price tag. Many more gene therapies are on their way. How can they be priced to hit the sweet spot of affordability, access, and innovation?

July 25, 2018

Managed Care

read full article >

Recent Insights

view archive >

November 18, 2018

What rebates? Express Scripts touts a new plan to appease critics of the opaque drug-pricing system

Amid national angst over prescription drug pricing, Express Scripts is touting a new scheme it says will lessen the behind-the-scenes role that rebates play in rising costs. In effect, Express Scripts would create a two-tier system for its customers which could choose between a formulary with a high list price and high rebate, or the newer plan that will offer a lower list price and lower or no rebate.

read full insight article >

November 5, 2018

Backing into Value with Part B

Jeff Berkowitz, CEO, Real Endpoints' is quoted, "It becomes a global index that reflects the value as seen by number of different entities against all of the other choices they need to make from a health delivery perspective."

read full insight article >